The authors indicated that it is reasonable to simultaneously employ a TIM-3-TIM-3L and PD-1-PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma [62]. This evidence concerns the gene PDCD1 and neoplasm.